Can quadrivalent human papillomavirus prophylactic vaccine be an effective alternative for the therapeutic management of genital warts? an exploratory study
To evaluate the treatment effect of genital warts, we investigated the quadrivalent HPV vaccine injection compared with surgical excision. This prospective study included 26 patients (M:F = 24:2) who received HPV vaccine or surgical excision. After explanation of surgical excision or HPV vaccine, 16...
Gespeichert in:
| Veröffentlicht in: | International Brazilian Journal of Urology 2019-03, Vol.45 (2), p.361-368 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 368 |
|---|---|
| container_issue | 2 |
| container_start_page | 361 |
| container_title | International Brazilian Journal of Urology |
| container_volume | 45 |
| creator | Choi, Hoon |
| description | To evaluate the treatment effect of genital warts, we investigated the quadrivalent HPV vaccine injection compared with surgical excision.
This prospective study included 26 patients (M:F = 24:2) who received HPV vaccine or surgical excision. After explanation of surgical excision or HPV vaccine, 16 patients underwent surgical excision and the others received HPV vaccine injections. Based on gross findings of genital warts, treatment outcomes were classified as complete response (no wart), partial response, and failed treatment.
Among enrolled patients, 42% (11 / 26) patients had recurrent genital warts. In vaccination group, complete response rates of genital wart were 60% following 3 times HPV vaccine. Partial response patients wanted to excise the genital lesions before the 3 times injection, because they worried about sexual transmission of disease to their sexual partners. One patient underwent surgical excision after 3 times injection. Excision sites included suprapubic lesions, but other sites including mid-urethra and glans showed complete response after injection. At a mean follow-up period of 8.42 ± 3.27 months, 10 patients (100%) who received HPV vaccine did not show recurrence.
The response rates after HPV vaccine injection were 90% (complete and partial). Our results suggested that HPV vaccines could be effective in management of genital warts. |
| doi_str_mv | 10.1590/S1677-5538.IBJU.2018.0355 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_doaj_</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6541142</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_1c10e81cf1594da991bd0d4a21b1f3c9</doaj_id><sourcerecordid>30785696</sourcerecordid><originalsourceid>FETCH-LOGICAL-c584t-5122d29ad3ca5e81ada7bae7e6c2aeb88ff33409228c7a7b89105d832aeea683</originalsourceid><addsrcrecordid>eNpVkdtu1DAURSMEoqXwC8h8wAy-xIn9AoIRlEGVeKA8Wye-zHjkxMG5lPkXPrbOTKnog-Xjs73XsbWL4h3Ba8Ilfv-TVHW94pyJ9fbz919riolYY8b5s-LyJFWEyOcP9XLtong1DAeMqcQ1eVlcMFwLXsnqsvi7gQ79nsAkP0Ow3Yj2U5tbPfQ-hNjC7NM0oD7Ffn8MoEev0Qxa-86ixqJ80zpnc3vOhzDa1MGpdjGhcW-XlaC30-LLXNjZdhkSHdrZzo8Q0B2kcfh4Iv3pQ0wwxnREwziZ4-vihYMw2DcP-1Vx-_XL7ebb6ubH9Xbz6WaluSjHFSeUGirBMA3cCgIG6gZsbStNwTZCOMdYiSWlQtdZEpJgbgTLooVKsKtie8aaCAfVJ99COqoIXp0aMe1UfqPXwSqiCc4TtMs5lAakJI3BpgRKGuKYlpn14czqp6a1RufPJghPoE-Vzu_VLs6q4iUhJc0AeQboFIchWffoJVgt6athiVUtsSrfHCa1pK-W9LP37f_DH53_4mb3iJizvQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Can quadrivalent human papillomavirus prophylactic vaccine be an effective alternative for the therapeutic management of genital warts? an exploratory study</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Choi, Hoon</creator><creatorcontrib>Choi, Hoon</creatorcontrib><description>To evaluate the treatment effect of genital warts, we investigated the quadrivalent HPV vaccine injection compared with surgical excision.
This prospective study included 26 patients (M:F = 24:2) who received HPV vaccine or surgical excision. After explanation of surgical excision or HPV vaccine, 16 patients underwent surgical excision and the others received HPV vaccine injections. Based on gross findings of genital warts, treatment outcomes were classified as complete response (no wart), partial response, and failed treatment.
Among enrolled patients, 42% (11 / 26) patients had recurrent genital warts. In vaccination group, complete response rates of genital wart were 60% following 3 times HPV vaccine. Partial response patients wanted to excise the genital lesions before the 3 times injection, because they worried about sexual transmission of disease to their sexual partners. One patient underwent surgical excision after 3 times injection. Excision sites included suprapubic lesions, but other sites including mid-urethra and glans showed complete response after injection. At a mean follow-up period of 8.42 ± 3.27 months, 10 patients (100%) who received HPV vaccine did not show recurrence.
The response rates after HPV vaccine injection were 90% (complete and partial). Our results suggested that HPV vaccines could be effective in management of genital warts.</description><identifier>ISSN: 1677-5538</identifier><identifier>ISSN: 1677-6119</identifier><identifier>EISSN: 1677-6119</identifier><identifier>DOI: 10.1590/S1677-5538.IBJU.2018.0355</identifier><identifier>PMID: 30785696</identifier><language>eng</language><publisher>Brazil: Sociedade Brasileira de Urologia</publisher><subject>Adult ; Condylomata Acuminata - immunology ; Condylomata Acuminata - prevention & control ; Condylomata Acuminata - surgery ; Female ; Follow-Up Studies ; Human papillomavirus 31 ; Humans ; Male ; Middle Aged ; Original ; Papillomaviridae ; Papillomavirus Infections - prevention & control ; Papillomavirus Infections - surgery ; Papillomavirus Infections - virology ; Papillomavirus Vaccines - administration & dosage ; Papillomavirus Vaccines - immunology ; Prospective Studies ; Therapeutics ; Treatment Outcome ; Vaccines ; Young Adult</subject><ispartof>International Brazilian Journal of Urology, 2019-03, Vol.45 (2), p.361-368</ispartof><rights>Copyright® by the International Brazilian Journal of Urology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c584t-5122d29ad3ca5e81ada7bae7e6c2aeb88ff33409228c7a7b89105d832aeea683</citedby><cites>FETCH-LOGICAL-c584t-5122d29ad3ca5e81ada7bae7e6c2aeb88ff33409228c7a7b89105d832aeea683</cites><orcidid>0000-0002-8481-8103</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541142/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541142/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30785696$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Choi, Hoon</creatorcontrib><title>Can quadrivalent human papillomavirus prophylactic vaccine be an effective alternative for the therapeutic management of genital warts? an exploratory study</title><title>International Brazilian Journal of Urology</title><addtitle>Int Braz J Urol</addtitle><description>To evaluate the treatment effect of genital warts, we investigated the quadrivalent HPV vaccine injection compared with surgical excision.
This prospective study included 26 patients (M:F = 24:2) who received HPV vaccine or surgical excision. After explanation of surgical excision or HPV vaccine, 16 patients underwent surgical excision and the others received HPV vaccine injections. Based on gross findings of genital warts, treatment outcomes were classified as complete response (no wart), partial response, and failed treatment.
Among enrolled patients, 42% (11 / 26) patients had recurrent genital warts. In vaccination group, complete response rates of genital wart were 60% following 3 times HPV vaccine. Partial response patients wanted to excise the genital lesions before the 3 times injection, because they worried about sexual transmission of disease to their sexual partners. One patient underwent surgical excision after 3 times injection. Excision sites included suprapubic lesions, but other sites including mid-urethra and glans showed complete response after injection. At a mean follow-up period of 8.42 ± 3.27 months, 10 patients (100%) who received HPV vaccine did not show recurrence.
The response rates after HPV vaccine injection were 90% (complete and partial). Our results suggested that HPV vaccines could be effective in management of genital warts.</description><subject>Adult</subject><subject>Condylomata Acuminata - immunology</subject><subject>Condylomata Acuminata - prevention & control</subject><subject>Condylomata Acuminata - surgery</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Human papillomavirus 31</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Original</subject><subject>Papillomaviridae</subject><subject>Papillomavirus Infections - prevention & control</subject><subject>Papillomavirus Infections - surgery</subject><subject>Papillomavirus Infections - virology</subject><subject>Papillomavirus Vaccines - administration & dosage</subject><subject>Papillomavirus Vaccines - immunology</subject><subject>Prospective Studies</subject><subject>Therapeutics</subject><subject>Treatment Outcome</subject><subject>Vaccines</subject><subject>Young Adult</subject><issn>1677-5538</issn><issn>1677-6119</issn><issn>1677-6119</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNpVkdtu1DAURSMEoqXwC8h8wAy-xIn9AoIRlEGVeKA8Wye-zHjkxMG5lPkXPrbOTKnog-Xjs73XsbWL4h3Ba8Ilfv-TVHW94pyJ9fbz919riolYY8b5s-LyJFWEyOcP9XLtong1DAeMqcQ1eVlcMFwLXsnqsvi7gQ79nsAkP0Ow3Yj2U5tbPfQ-hNjC7NM0oD7Ffn8MoEev0Qxa-86ixqJ80zpnc3vOhzDa1MGpdjGhcW-XlaC30-LLXNjZdhkSHdrZzo8Q0B2kcfh4Iv3pQ0wwxnREwziZ4-vihYMw2DcP-1Vx-_XL7ebb6ubH9Xbz6WaluSjHFSeUGirBMA3cCgIG6gZsbStNwTZCOMdYiSWlQtdZEpJgbgTLooVKsKtie8aaCAfVJ99COqoIXp0aMe1UfqPXwSqiCc4TtMs5lAakJI3BpgRKGuKYlpn14czqp6a1RufPJghPoE-Vzu_VLs6q4iUhJc0AeQboFIchWffoJVgt6athiVUtsSrfHCa1pK-W9LP37f_DH53_4mb3iJizvQ</recordid><startdate>20190301</startdate><enddate>20190301</enddate><creator>Choi, Hoon</creator><general>Sociedade Brasileira de Urologia</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-8481-8103</orcidid></search><sort><creationdate>20190301</creationdate><title>Can quadrivalent human papillomavirus prophylactic vaccine be an effective alternative for the therapeutic management of genital warts? an exploratory study</title><author>Choi, Hoon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c584t-5122d29ad3ca5e81ada7bae7e6c2aeb88ff33409228c7a7b89105d832aeea683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Condylomata Acuminata - immunology</topic><topic>Condylomata Acuminata - prevention & control</topic><topic>Condylomata Acuminata - surgery</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Human papillomavirus 31</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Original</topic><topic>Papillomaviridae</topic><topic>Papillomavirus Infections - prevention & control</topic><topic>Papillomavirus Infections - surgery</topic><topic>Papillomavirus Infections - virology</topic><topic>Papillomavirus Vaccines - administration & dosage</topic><topic>Papillomavirus Vaccines - immunology</topic><topic>Prospective Studies</topic><topic>Therapeutics</topic><topic>Treatment Outcome</topic><topic>Vaccines</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Choi, Hoon</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International Brazilian Journal of Urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Choi, Hoon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Can quadrivalent human papillomavirus prophylactic vaccine be an effective alternative for the therapeutic management of genital warts? an exploratory study</atitle><jtitle>International Brazilian Journal of Urology</jtitle><addtitle>Int Braz J Urol</addtitle><date>2019-03-01</date><risdate>2019</risdate><volume>45</volume><issue>2</issue><spage>361</spage><epage>368</epage><pages>361-368</pages><issn>1677-5538</issn><issn>1677-6119</issn><eissn>1677-6119</eissn><abstract>To evaluate the treatment effect of genital warts, we investigated the quadrivalent HPV vaccine injection compared with surgical excision.
This prospective study included 26 patients (M:F = 24:2) who received HPV vaccine or surgical excision. After explanation of surgical excision or HPV vaccine, 16 patients underwent surgical excision and the others received HPV vaccine injections. Based on gross findings of genital warts, treatment outcomes were classified as complete response (no wart), partial response, and failed treatment.
Among enrolled patients, 42% (11 / 26) patients had recurrent genital warts. In vaccination group, complete response rates of genital wart were 60% following 3 times HPV vaccine. Partial response patients wanted to excise the genital lesions before the 3 times injection, because they worried about sexual transmission of disease to their sexual partners. One patient underwent surgical excision after 3 times injection. Excision sites included suprapubic lesions, but other sites including mid-urethra and glans showed complete response after injection. At a mean follow-up period of 8.42 ± 3.27 months, 10 patients (100%) who received HPV vaccine did not show recurrence.
The response rates after HPV vaccine injection were 90% (complete and partial). Our results suggested that HPV vaccines could be effective in management of genital warts.</abstract><cop>Brazil</cop><pub>Sociedade Brasileira de Urologia</pub><pmid>30785696</pmid><doi>10.1590/S1677-5538.IBJU.2018.0355</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-8481-8103</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1677-5538 |
| ispartof | International Brazilian Journal of Urology, 2019-03, Vol.45 (2), p.361-368 |
| issn | 1677-5538 1677-6119 1677-6119 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6541142 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central |
| subjects | Adult Condylomata Acuminata - immunology Condylomata Acuminata - prevention & control Condylomata Acuminata - surgery Female Follow-Up Studies Human papillomavirus 31 Humans Male Middle Aged Original Papillomaviridae Papillomavirus Infections - prevention & control Papillomavirus Infections - surgery Papillomavirus Infections - virology Papillomavirus Vaccines - administration & dosage Papillomavirus Vaccines - immunology Prospective Studies Therapeutics Treatment Outcome Vaccines Young Adult |
| title | Can quadrivalent human papillomavirus prophylactic vaccine be an effective alternative for the therapeutic management of genital warts? an exploratory study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T20%3A04%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Can%20quadrivalent%20human%20papillomavirus%20prophylactic%20vaccine%20be%20an%20effective%20alternative%20for%20the%20therapeutic%20management%20of%20genital%20warts?%20an%20exploratory%20study&rft.jtitle=International%20Brazilian%20Journal%20of%20Urology&rft.au=Choi,%20Hoon&rft.date=2019-03-01&rft.volume=45&rft.issue=2&rft.spage=361&rft.epage=368&rft.pages=361-368&rft.issn=1677-5538&rft.eissn=1677-6119&rft_id=info:doi/10.1590/S1677-5538.IBJU.2018.0355&rft_dat=%3Cpubmed_doaj_%3E30785696%3C/pubmed_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30785696&rft_doaj_id=oai_doaj_org_article_1c10e81cf1594da991bd0d4a21b1f3c9&rfr_iscdi=true |